Chemical Technology, Science and Research

Lithium batteries whitepaper

December 25, 2022

Lithium batteries
Founded in 1903, Brookes Bell is a leading multi-disciplinary technical and scientific consultancy serving the marine and energy sectors. We investigate, troubleshoot and advise on a broad range of marine and energy matters and enjoy a reputation.

Spotlight

IMMUNE Pharmaceuticals Inc.

Immune Pharmaceuticals applies a personalized approach to treating and developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. Immune's lead product candidate, bertilimumab, is in clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan auto-immune dermatological condition. Other indications considered for development include atopic dermatitis, Crohn's disease, severe asthma and NASH (inflammatory liver disease). Immune recently expanded its portfolio in immuno-dermatology, topical nano-formulated Cyclosporine A for the treatment of psoriasis and atopic dermatitis. Immune's pipeline also includes NanomAbs®, antibody nano-conjugates, for the targeted delivery of chemotherapeutics. Immune's Pain pipeline including AmiKet™ are in a partnering process for further development and commercialization.

OTHER WHITEPAPERS
news image

White Paper on the Low-carbon Development of the Petrochemical Industry

whitePaper | April 22, 2022

As the impacts of climate change increase, China announced the goal of "striving to peak CO2 emissions by 2030 and achieve carbon neutrality by 2060".

Read More
news image

Analysis of Hand Sanitizers to Support Label Claims

whitePaper | April 30, 2021

At the height of the first wave of the COVID-19 pandemic, consumers around the world experienced a supply shortage related to alcohol-based hand sanitizer. As new producers entered the market, and existing manufacturers sought to ramp-up production to meet the growing demand, lower grades of ethanol and isopropanol (IPA) started to appear on the market. To ensure the safety and efficacy of hand sanitizer products, it is recommended that manufacturers test their products to ensure appropriate levels of active ingredients, as well as a means of ensuring label-claim accuracy. In this application note, an efficient and simple, “dilute and shoot” method for the analysis of IPA and ethanol in hand sanitizer products is detailed. With a run-time of only 5.36 minutes per sample, this method is ideal for operations requiring fast turnaround times that won’t disrupt the production of their products.

Read More
news image

Solutions for Ammonia Gas Detection: A Comparison Summary

whitePaper | October 21, 2022

The hazardous, toxic, and combustible nature of ammonia is wellknown in industrial settings. Undetected ammonia leaks in production

Read More
news image

Advanced Recycling: Seizing the Circular Plastics Opportunity

whitePaper | March 11, 2022

Our modern way of life would not be possible without plastics. However, better post-use management of plastic products is required, and we need to move to a circular economy for plastics that recognizes plastics as a resource or feedstock, not a waste.

Read More
news image

HOW DNAENCODED LIBRARIES ARE REINVENTING HIT IDENTIFICATION

whitePaper | June 21, 2022

The concept behind DEL screening is simple. Combinatorial chemistry is used to rapidly build huge libraries of diverse compounds from a set of chemical building blocks.

Read More
news image

Why Deck 7

whitePaper | January 1, 2020

With over 2,800 campaigns each year delivered through a team of 300+ digital, data, and technology specialists, Deck 7 is a first resource for B2B demand generation services for marketers worldwide. Clients leverage Deck 7’s multichannel content marketing services and Media 7’s network of 30+ online publications for content syndication to engage over 95 million buyers across 16 industries and 120+ countries.

Read More

Spotlight

IMMUNE Pharmaceuticals Inc.

Immune Pharmaceuticals applies a personalized approach to treating and developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. Immune's lead product candidate, bertilimumab, is in clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan auto-immune dermatological condition. Other indications considered for development include atopic dermatitis, Crohn's disease, severe asthma and NASH (inflammatory liver disease). Immune recently expanded its portfolio in immuno-dermatology, topical nano-formulated Cyclosporine A for the treatment of psoriasis and atopic dermatitis. Immune's pipeline also includes NanomAbs®, antibody nano-conjugates, for the targeted delivery of chemotherapeutics. Immune's Pain pipeline including AmiKet™ are in a partnering process for further development and commercialization.

Events